Advertisement
Par marketed meclizine prior to an explosion at the facility of its APIsupplier in February 2008. Par has since qualified a new API source andreceived the appropriate approval of its supplemental new drug application tomanufacture and market meclizine HCl utilizing its new API supplier.
Advertisement
Important information about meclizine
Meclizine is an oral antiemetic indicated for the prevention and treatmentof nausea, vomiting, and dizziness associated with motion sickness. It iscontraindicated in individuals who have shown a previous hypersensitivity toit.
About Par Pharmaceutical
Par Pharmaceutical, Inc. develops, manufactures and markets generic drugsand innovative branded pharmaceuticals for specialty markets. For pressrelease and other company information, visit www.parpharm.com.
Safe Harbor Statement
Certain statements in this press release constitute "forward-lookingstatements" within the meaning of the Private Securities Litigation Reform Actof 1995. To the extent any statements made in this news release containinformation that is not historical, these statements are essentiallyforward-looking and, as such, are subject to risks and uncertainties,including the extent and impact of litigation arising out of the accountingissues described in the Company's filings with the Securities and ExchangeCommission (SEC), the difficulty of predicting FDA filings and approvals,acceptance and demand for new pharmaceutical products, the impact ofcompetitive products and pricing, new product development and launch, relianceon key strategic alliances, uncertainty of patent litigation filed against theCompany, availability of raw materials, the regulatory environment,fluctuations in operating results and other risks and uncertainties detailedfrom time to time in the company's filings with the SEC, such as the Company'sreports on Form 10-K, Form 10-Q and Form 8-K, and amendments thereto. Anyforward-looking statements included in this press release are made as of thedate hereof only, based on information available to the Company as of the datehereof, and, subject to any applicable law to the contrary, the Companyassumes no obligation to update any forward-looking statements.
SOURCE Par Pharmaceutical Companies, Inc.
